Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data BioSpaceThe FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.RegulatoryMetabolic & GLP-1Read full story pharminent April 15, 2026 BioSpace The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July. RegulatoryMetabolic & GLP-1Read full story Post navigation Previous: Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In SilicoNext: Amazon launches its AI drug discovery platform Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
